Q2 earnings arrive as pharma picks up steam, buoyed by dealmaking, policy tailwinds

Biopharma is entering its second-quarter earnings season riding high on a wave of massive deals and venture capital flow, plus a clearing of regulatory and policy overhangs. What can industry watchers expect to hear on the upcoming investor calls?